OJJAARA 100 MG
MOMELOTINIB (MOMELOTINIB DIHYDROCHLORIDE) : 100 MG · DIN 02552965 · GLAXOSMITHKLINE INC
Health Canada status: MARKETED
What is OJJAARA?
OJJAARA 100 MG contains MOMELOTINIB (MOMELOTINIB DIHYDROCHLORIDE) : 100 MG. It is listed in the Health Canada Drug Product Database under DIN 02552965, held by GLAXOSMITHKLINE INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 21-Jan-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is OJJAARA used for?
Treatment of splenomegaly and/or disease-related symptoms in adults with intermediate or high-risk primary or secondary myelofibrosis (MF) who have moderate to severe anemia.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02552965 |
|---|---|
| Brand name | OJJAARA |
| Generic / active ingredient | MOMELOTINIB (MOMELOTINIB DIHYDROCHLORIDE) : 100 MG |
| Manufacturer | GLAXOSMITHKLINE INC |
| Strength | 100 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | L01EJ04 MOMELOTINIB |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 21-Jan-2025 |
How is it administered?
Recommended dosage is 200 mg taken orally once daily. Should not be used with other JAK inhibitors. Swallow whole; do not cut, crush, or chew. May be taken with or without food.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
(Specific temperature range not provided in text; refer to section 11).
How is it supplied?
100 mg, 150 mg, and 200 mg film-coated tablets. (Specific bottle counts not provided in text).
Contraindications
Hypersensitivity to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container.
Warnings and precautions
Serious bacterial and viral infections (some fatal). Risk of secondary malignancies, thrombosis (DVT/PE), MACE, hepatotoxicity, thrombocytopenia, and neutropenia. Contains lactose.
What can be used instead?
Other Canadian products sharing ATC code L01EJ04 MOMELOTINIB. 3 of 3 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| OJJAARA | 150 MG | TABLET | GLAXOSMITHKLINE INC | MARKETED | DIN 02552973 |
| OJJAARA | 200 MG | TABLET | GLAXOSMITHKLINE INC | MARKETED | DIN 02552981 |
Who else supplies MOMELOTINIB worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. MOMELOTINIB appears in 27 registered pack listings across 8 markets, published on 7 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.